OSRX Teams Up with Pro Rodeo Standout Sam Petersen Following Breakout 2025 Season

MISSOULA, Mont.--(BUSINESS WIRE)--OSRX, Inc., an FDA-registered outsourcing facility specializing in compounded ophthalmic medications, today announced a partnership with professional rodeo athlete and Montana native Sam Petersen—the 2025 world No. 2 bareback rider and Wrangler National Finals Rodeo average champion. The collaboration advances the company’s Ride with OSRX campaign—an initiative celebrating rising American talent forged through discipline, resilience, and a relentless pursuit of excellence.

Both Petersen and OSRX share roots in Montana—and a competitive mindset built on performance. Known for his grit in and out of the arena, Petersen competes with consistency, control, and the ability to execute under extreme pressure. OSRX applies those same standards to compounded ophthalmic medications, where precision and reliability directly impact patient outcomes. That focus has fueled the company’s rapid growth from a Missoula startup into one of the nation’s largest ophthalmic compounders, now trusted by more than 10,000 prescribers nationwide.

“Montana breeds a certain type of person—and company,” said Eric Garner, Chief Commercial Officer at OSRX. “When you watch Sam ride, you see someone who demands more of himself every single time out. That attitude is exactly how OSRX was built—by doing things the right way, earning trust, and delivering consistently when it matters most. As we continue to grow nationally, partnering with Sam is a natural extension of who we are and where we’re going.”

Petersen echoed the connection between their disciplines. “There’s a lot of overlap in how we think about what we do,” Petersen said. “For me, it’s about putting in the work and performing at the highest level every time I nod my head. You can tell OSRX takes pride in getting the details right and producing great medications.”

Founded in 2019, OSRX formulates compounded ophthalmic medications designed to simplify post-surgical care and support ongoing treatment for conditions such as glaucoma. By streamlining dosing and prioritizing affordable pricing regardless of insurance status, the company is working to expand access to quality, affordable eye care for everyday Americans.

“At the end of the day, performance matters—whether it’s in rodeo or medicine,” Garner added. “We believe patients and providers shouldn’t have to choose between quality care and affordability. That’s what we’re creating, and that’s what Ride with OSRX represents.”

Petersen becomes the latest athlete supported through Ride with OSRX, joining a growing roster of next-generation competitors across high-performance sports, including racing phenom Truly Adams, who is pursuing a pathway to Formula 1. The partnership will include national marketing campaigns, event appearances, and digital content series throughout 2026, featuring behind-the-scenes training, competition coverage, and storytelling from the road.

As Petersen pushes toward a world title in 2026, OSRX will support his journey—reinforcing a shared belief at the core of the campaign: success is earned, not given.

Learn more about OSRX and follow Petersen’s 2026 season through the Ride with OSRX campaign at ridewithosrx.com.

About OSRX

OSRX is an FDA-registered 503B outsourcing facility dedicated to advancing ophthalmic care through high-quality compounded solutions that simplify treatment for prescribers and patients. Operating nationwide, the Montana-based company is trusted by more than 10,000 prescribers and is driven by its vision to deliver high-quality medications at affordable prices. Learn more at www.osrxpharmaceuticals.com.

OSRX glaucoma and other compounded medications carry serious risks, including elevation of intraocular pressure, conjunctivitis, and decreased visual acuity. View potential adverse events and contraindications at: https://osrxpharmaceuticals.com/osrx-api-aecontraindication. For professional use only. OSRX specializes in customizing compounded medications to meet unique patient needs. Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality.